Phio Pharmaceuticals Announces New Chief Financial Officer
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Cancer
Phio Pharmaceuticals Announces New Chief Financial Officer
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health’s Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August...
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health’s Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August...
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous systemBRAINTREE, Mass.,...
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet...
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting – Key SABRE Update Also Expected
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical...
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.,...
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support...
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ETNEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE)...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Kura Oncology to Report Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development,...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone...
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical...
Biobanking Market size is set to grow by USD 1.66 billion from 2024-2028, Growing demand for personalized medicine boost the market, Technavio
NEW YORK, July 31, 2024 /PRNewswire/ -- The global biobanking market size is estimated to grow by USD 1.66 billion from 2024-2028, according...